152 related articles for article (PubMed ID: 37325333)
1. Comparison of treatment costs for primary localized prostate cancer in Austria and Vienna: an economic analysis.
Moll M; Goldner G
Front Public Health; 2023; 11():1016860. PubMed ID: 37325333
[TBL] [Abstract][Full Text] [Related]
2. International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy.
Berlin A; Moraes FY; Sanmamed N; Glicksman R; Koven A; Espin-Garcia O; Leite ETT; Silva JLF; Gadia R; Nesbitt M; Catton CN; Kaffenberger S; Salami SS; Morgan TM; Hearn JWD; Jackson WC; Mehra R; Chung P; Fleshner NE; Zumsteg ZS; Dess RT; Feng FY; Finelli A; Spratt DE
J Urol; 2019 Feb; 201(2):284-291. PubMed ID: 30153435
[TBL] [Abstract][Full Text] [Related]
3. Evolution of definitive external beam radiation therapy in the treatment of prostate cancer.
Daly T
World J Urol; 2020 Mar; 38(3):565-591. PubMed ID: 30850855
[TBL] [Abstract][Full Text] [Related]
4. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
[TBL] [Abstract][Full Text] [Related]
5. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
[TBL] [Abstract][Full Text] [Related]
6. [Cost comparison of three treatments for localized prostate cancer in Spain: radical prostatectomy, prostate brachytherapy and external 3D conformal radiotherapy].
Becerra Bachino V; Cots F; Guedea F; Pera J; Boladeras A; Aguiló F; Suárez JF; Gallo P; Murgui L; Pont A; Cunillera O; Pardo Y; Ferrer M;
Gac Sanit; 2011; 25(1):35-43. PubMed ID: 21316126
[TBL] [Abstract][Full Text] [Related]
7. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
Grimm P; Billiet I; Bostwick D; Dicker AP; Frank S; Immerzeel J; Keyes M; Kupelian P; Lee WR; Machtens S; Mayadev J; Moran BJ; Merrick G; Millar J; Roach M; Stock R; Shinohara K; Scholz M; Weber E; Zietman A; Zelefsky M; Wong J; Wentworth S; Vera R; Langley S
BJU Int; 2012 Feb; 109 Suppl 1():22-9. PubMed ID: 22239226
[TBL] [Abstract][Full Text] [Related]
9. Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer.
Mohiuddin JJ; Narayan V; Venigalla S; Vapiwala N
Brachytherapy; 2019; 18(3):322-331. PubMed ID: 30862436
[TBL] [Abstract][Full Text] [Related]
10. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
11. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.
Elliott SP; Meng MV; Elkin EP; McAninch JW; Duchane J; Carroll PR;
J Urol; 2007 Aug; 178(2):529-34; discussion 534. PubMed ID: 17570425
[TBL] [Abstract][Full Text] [Related]
12. [Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study].
Reinhold T; Dornquast C; Börgermann C; Weißbach L
Urologe A; 2016 Dec; 55(12):1573-1585. PubMed ID: 27822603
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis.
Greenberger BA; Zaorsky NG; Den RB
Eur Urol Focus; 2020 Mar; 6(2):404-418. PubMed ID: 31813810
[TBL] [Abstract][Full Text] [Related]
14. An economic analysis of conservative management versus active treatment for men with localized prostate cancer.
Perlroth DJ; Bhattacharya J; Goldman DP; Garber AM
J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):250-7. PubMed ID: 23271781
[TBL] [Abstract][Full Text] [Related]
15. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
Cooperberg MR; Vickers AJ; Broering JM; Carroll PR
Cancer; 2010 Nov; 116(22):5226-34. PubMed ID: 20690197
[TBL] [Abstract][Full Text] [Related]
16. Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: a comparison of Australian series.
Wilcox SW; Aherne NJ; McLachlan CS; McKay MJ; Last AJ; Shakespeare TP
J Med Imaging Radiat Oncol; 2015 Feb; 59(1):125-33. PubMed ID: 25588566
[TBL] [Abstract][Full Text] [Related]
17. The Patient Burden of Bladder Outlet Obstruction after Prostate Cancer Treatment.
Liberman D; Jarosek S; Virnig BA; Chu H; Elliott SP
J Urol; 2016 May; 195(5):1459-1463. PubMed ID: 26682759
[TBL] [Abstract][Full Text] [Related]
18. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
[TBL] [Abstract][Full Text] [Related]
19. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
[TBL] [Abstract][Full Text] [Related]
20. Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy.
Schlussel Markovic E; Buckstein M; Stone NN; Stock RG
BJU Int; 2018 May; 121(5):774-780. PubMed ID: 29319919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
